307
Views
9
CrossRef citations to date
0
Altmetric
ReviewsOvarian Hyperstimulation Syndrome

Dopamine agonists in prevention of ovarian hyperstimulation syndrome

, , , , , & show all
Pages 845-849 | Received 21 Jan 2014, Accepted 08 Jul 2014, Published online: 05 Aug 2014

References

  • Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–7
  • Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112–20
  • Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559–77
  • Fiedler K, Ezcurra D. Predicting and preventing of ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;24:10–32
  • Papanikolaou EG, Humaidan P, Polyzos N, et al. New algorhitm for prevention of OHSS. Reprod Biol Endocrinol 2011;9:147–50
  • Genazzani AR, Monteleone P, Papini F, Artini PG. Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opin Pharmacother 2010;11:2527–34
  • Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11
  • Youssef MA, van Vely M, Hassan MA, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459–66
  • Busso C, Garcia-Velasco J, Gomez R, et al. Symposium: update on prediction and management of OHSS: prevention of OHSS-dopamine agonists. Reprod Biomed Online 2009;19:143–51
  • Soares SR, Gomez R, Simon C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321–33
  • Fiedler K, Ezcurra D. Predicting and preventing of ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;10:32–7
  • Villasante A, Pacheco A, Pau E, et al. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 2008;23:662–7
  • Rodewald M, Herr D, Duncan WC, et al. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod 2009;24:1191–9
  • Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010;28:448–57
  • Basu S, Nagy JA, Vasile E, et al. The neurotransmiter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothealial growth factor. Nat Med 2001;7:569–74
  • Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005;122:127–8
  • Álvarez C, Martí-Bonmatí L, Novela-Maestre E, et al. Dopamine agonist cabergoline reduces haemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7
  • Carizza C, Abdelmassih S, Ravizzini P, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751–5
  • Salah Edeen AMR, Alhelou YM. Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE; 28 June–1 July 2009; Amsterdam, The Netherlands
  • Shaltout A, Shohayeb A, Eid M, Abbas S. Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE; 28 June–1 July 2009; Amsterdam, The Netherlands
  • Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012;2:CD0086005
  • Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009;92:1168.e1–4
  • Shaltout A, Shohyab A, Youssef MA. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 2012;165:254–8
  • Seow KM, Lin YH, Bai CH, et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online 2013;26:562–8
  • Tehraninenjad ES, Hafezi M, Arabipoor A, et al. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 2012;29:259–64
  • Esinler I, Bozdaq G, Karakosokmesuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet 2013;288:1159–63
  • Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl Med J 2007;356:29–38
  • Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826–9
  • Izgi C, Feray H, Cevik C, et al. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis 2010;19:797–800
  • Valette S, Semi K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009;12:153–7
  • Drake W, Stiles C, Howlett T, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 2014;99:90–6
  • Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6–9
  • Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39–46
  • Busso C, Fernández-Sánchez M, García-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25:995–1004
  • Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152–64
  • Spitzer D, Wogatzky J, Murtinger M, et al. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2011;95:2742–4
  • Sherwal V, Malik S, Bhatia V. Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. J Hum Reprod Sci 2010;3:85–90
  • Baumgarten M, Polanski L, Campbell B, Raine-Fenning N. Do dopamine agonists prevent or reduce the severity ovarian hypestimulation syndrome in women undergoig assisted reproduction? A systematic review and meta-analysis. Hum Fertil (Camb) 2013;16:168–74
  • Soares SR. Etiology of OHSS and the use of dopamine agonists. Fertil Steril 2012;97:517–22

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.